TrialMedicine2018

Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.

Yo Han Ahn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.